Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3921)
All Articles published online
|
Nov 21, 2012 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Su QM, Ye XG. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis. World J Gastroenterol 2012; 18(43): 6290-6301 [PMID: 23180951 DOI: 10.3748/wjg.v18.i43.6290] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i43/6290.htm |
| Number | Citing Articles |
| 1 |
Siu‐Tong Law, Ming Kai Lee, Ann Shing Lee, Yuk Tung, Kin Kong Li. Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy. Journal of Digestive Diseases 2016; 17(5): 325 doi: 10.1111/1751-2980.12349
|
| 2 |
Isobel D. Ramsay, Jodi M. Lestner, Catherine P. O’Sullivan, Ana L.G. Cruz, Ho Kwong Li, Charlotte I.S. Barker. A worldwide yearly survey of new data in adverse drug reactions. Side Effects of Drugs Annual 2014; 36: 401 doi: 10.1016/B978-0-444-63407-8.00029-0
|
| 3 |
Hsien-Chung Yu, Kung-Hung Lin, Ping-I Hsu, Feng-Woei Tsay, Huay-Min Wang, Tzung-Jiun Tsai, Kwok-Hung Lai. Real-World Application of the Roadmap Model in Chronic Hepatitis B Patients with Telbivudine Therapy. Clinical Therapeutics 2013; 35(9): 1386 doi: 10.1016/j.clinthera.2013.07.329
|
| 4 |
Yi Shen, Yulong Jia, Jie Zhou, Juling Ji, Pengcheng Xun. Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. Clinical Drug Investigation 2019; 39(9): 835 doi: 10.1007/s40261-019-00802-8
|
| 5 |
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clinical and Molecular Hepatology 2020; 26(4): 411 doi: 10.3350/cmh.2020.0049
|
| 6 |
Xia Tang, Wenxun Huang, Juan Kang, Keyue Ding. Early dynamic changes of quasispecies in the reverse transcriptase region of hepatitis B virus in telbivudine treatment. Antiviral Research 2021; 195: 105178 doi: 10.1016/j.antiviral.2021.105178
|
| 7 |
Chia-Chi Wang, Chih-Lin Lin, Tsai-Yuan Hsieh, Kuo-Chih Tseng, Cheng-Yuan Peng, Tung-Hung Su, Sheng-Shun Yang, Yu-Chun Hsu, Tsung-Ming Chen, Jia-Horng Kao. Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. Hepatology International 2016; 10(2): 294 doi: 10.1007/s12072-015-9662-9
|
| 8 |
Guan-Huei Lee, David Hsingyu Chen, Seng-Gee Lim. Future Therapy for Hepatitis B Virus: Role of Nucleos(t)ide Analogues and Pegylated Interferon Therapy. Current Hepatology Reports 2016; 15(4): 230 doi: 10.1007/s11901-016-0325-7
|
| 9 |
Bircan Kayaaslan, Rahmet Guner. Adverse effects of oral antiviral therapy in chronic hepatitis B. World Journal of Hepatology 2017; 9(5): 227-241 doi: 10.4254/wjh.v9.i5.227
|
| 10 |
Y. Zhang, P. Hu, X. Qi, H. Ren, R.-C. Mao, J.-M. Zhang. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China. Clinical Microbiology and Infection 2016; 22(3): 287.e1 doi: 10.1016/j.cmi.2015.10.024
|